USA jobs

Meningococcal Vaccines Market Size, Industry Trends, Share, Growth and Report 2023-2028

No comments

The latest report by IMARC Group, titled “Meningococcal Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028″. The global meningococcal vaccines market size reached US$ 3.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.7% during 2023-2028.

Meningococcal vaccines are biological substances used to prevent meningitis, a contagious infection that affects the membranes surrounding the brain and spinal cord. They are widely available in three main types: conjugate, polysaccharide, and subcapsular meningococcal vaccines. They trigger the production of antibodies that fight the bacteria and create an immune response, thereby preventing future infections. At present, meningococcal vaccines are commonly administered to infants, children, and adults to protect them against the invasive disease caused by meningococcal bacteria A, B, C, W-135, and Y.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/meningococcal-vaccines-market/requestsample

Meningococcal Vaccines Market Trends and Drivers:

Other Post You May Be Interested In

The global meningococcal vaccines market is primarily driven by the increasing prevalence of the disease among young children and adolescents. Moreover, the rising awareness about health and well-being among the masses and the widespread adoption of routine immunization programs are positively influencing market growth. Additionally, the surging use of meningococcal vaccines, which help prevent the disease and reduce the risks of its long-term effects, such as permanent deafness, vision loss, and neurological damage, has catalyzed market growth. Furthermore, the development of ready-to-use liquid formulations that do not require reconstitution is contributing to the market growth. Other factors, including ongoing research and development (R&D) activities, the launch of public health programs, especially by governments of various developed and emerging economies, and continual improvements in healthcare infrastructure, are also anticipated to propel the market growth.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Vaccine Type:

  • Conjugate
  • Polysaccharide
  • Subcapsular

Breakup by Composition:

  • Mono Vaccines
  • Combination Vaccines

Breakup by Vaccine Serotype:

  • MenACWY
  • MenB & Manic
  • MenC
  • MenA
  • MenAC
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Institutional Sales
  • Others

Breakup by End User:

  • Pediatric
  • Adult

Breakup by Region:

  • North America (U.S. & Canada)
  • Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Others)
  • Asia Pacific (China, India, Japan, South Korea, Indonesia, Australia, and Others)
  • Latin America (Brazil, Mexico)
  • Middle East & Africa

Competitors Landscape with Key Players:

  • GlaxoSmithKline Plc
  • Hualan Biological Engineering Inc.
  • Incepta Pharmaceuticals Limited
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Ltd.
  • Walvax Biotechnology Co. Ltd.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

Follow us on Twitter: @imarcglobal

SHARE NOW
Tagged with

Leave a Reply

Your email address will not be published. Required fields are marked *